[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Combined Military Hospital, Pakistan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100633339","comparative-evaluation-of-oral-ursodeoxycholic-acid-in-reducing-bilirubin-levels-among-patients-with-acute-viral-hepatitis-100633339",false,"NCT07525401","Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis","AVH","Inclusion Criteria:\n\n* All patients of either gender\n* aged \\>18 years to 50 years with acute viral hepatitis are included\n\nExclusion Criteria:\n\n* Patients having Hepatitis B, C\n* hepatocellular carcinoma\n* primary biliary cholangitis\n* choldocholithiasis\n* patients having normal bilirubin levels with AVH were excluded.","ALL","18 Years","50 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hepatitis is an inflammatory condition of the liver that has emerged as a significant global health concern due to its widespread prevalence.\n\nData on ursodeoxycholic acid in acute viral hepatitis remain limited. Some studies suggest its positive effect in cholestatic phase of viral hepatitis. UDCA may reduce cholestatic symptoms like jaundice and pruritus potentially shortening hospital stay and improving patient outcomes. However, robust clinical data supporting its routine use in acute viral hepatitis are lacking, and current treatment remains largely supportive. Given the high burden of acute viral hepatitis in our region and the potential for UDCA to improve cholestatic phase of AVH there is a clear need for well-designed clinical studies evaluating its therapeutic role. This study aims to evaluate the role of oral ursodeoxycholic acid in biochemical recovery of patients with acute viral hepatitis. If positive role is confirmed, it will be incorporated in standard treatment and if no role is found unnecessary use will be discouraged.\n\nNull Hypothesis (H₀):\n\nOral ursodeoxycholic acid has no significant effect on the bilirubin levels of patients with acute viral hepatitis.\n\nH₀: There is no statistically significant difference in bilirubin levels between patients receiving ursodeoxycholic acid and those receiving supportive care alone.\n\nAlternative Hypothesis (H₁):\n\nOral ursodeoxycholic acid reduces bilirubin levels in patients with acute viral hepatitis. H₁: There is statistically significant difference in bilirubin levels between patients receiving ursodeoxycholic acid and those receiving supportive care alone.",[27,28],"Hepatitis A","Hepatitis E Virus Infection",[30,31,32,27,33],"Acute viral hepatitis","Ursodeoxycholic acid","UDCA","Hepatitis E","NOT_YET_RECRUITING","2026-04-10",{"date":37,"type":38},"2026-04-13","ACTUAL",{"date":40,"type":21},"2026-04",{"date":42,"type":21},"2026-10",{"name":44,"class":45},"Combined Military Hospital, Pakistan","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100536614","phase-3-comparative-efficacy-of-hypertonic-saline-vs-adrenaline-nebulization-in-acute-bronchiolitis-100536614","NCT06267118","Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis","A Randomized Controlled Trial on the Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis in Children","children","Inclusion Criteria:\n\n* All children admitted in PICU with acute bronchiolitis\n\nExclusion Criteria:\n\n* children with co-exiting illnesses like\n\n  1. Congenital Heart Disease\n  2. Immunodeficiency\n  3. other Infectious disease like Meningitis, encephalitis, Pneumonia, TORCH\n  4. Kidneys or liver problem\n  5. Seizures","1 Month","2 Years",{"count":57,"type":21},60,[59],"PHASE3","The goal of this clinical trial is to compare the efficacy of hypertonic saline nebulization with adrenaline nebulization in the treatment of acute bronchiolitis in children. Main aim is to evaluate the following in both group of patients\n\n1. Improvement in Wood-Downes clinical score (WDF score) in bronchiolitis\n2. Length of Hospitalization",[62],"Acute Bronchiolitis Due to Respiratory Syncytial Virus",[64],"Wood-Downes Clinical scoring System","RECRUITING","2024-08-21",{"date":68,"type":38},"2024-08-22",{"date":70,"type":38},"2023-11-01",{"date":72,"type":21},"2024-12-31",{"name":44,"class":45},1,""]